The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Mehdi Bsilat discussing the impact ...

(UroToday.com) The 2026 European Society of Medical Oncology (ESMO) Annual Congress held the session: Genitourinary tumour, ...

The 2026 European Society for Medical Oncology (ESMO) Annual Congress held Poster 2279P - ERG-Dependent Prognostic Impact of ...

Most CTC-evaluable patients in TALAPRO-2 had relatively low CTC burden at baseline, with 81.5% having <5 CTCs/7.5 mL and 65.3 ...

This was a retrospective, single-center study conducted at a tertiary referral center between 2007 and 2024. Patients who ...

Radical cystectomy remains a major operation even at experienced centers and with robotic surgical techniques. Data from the ...

The 2026 ESMO annual meeting featured a rapid oral session and a discussant presentation by Dr. Alison Reid discussing three ...

(UroToday.com) At the 2026 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Laurence Albiges and colleagues presented the study design of LUTEON, an ongoing, randomized phase III ...

This analysis included 58 patients treated with gemcitabine intravesical system monotherapy in the SunRISe-1 cohort who had ...

A total of 25 patients who received ≥2 cycles of toripalimab combined with TIP chemotherapy were enrolled. The objective response rate was 84.0%, with 2 patients achieving complete response and 19 ...

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed ...

(UroToday.com) The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alexander Decruyenaere discussing an ancillary study of the ProBio trial assessing the ...